Company reports positive results from evaluation of new solid tumor treatment.

2003 MAY 19 - (NewsRx.com & NewsRx.net) -- Northwest Biotherapeutics, Inc., (NWBT) announced positive findings from a recently completed preclinical mouse tumor evaluation of its new product candidate, DCVax-Direct Adjuvant Cancer Therapy, which is designed to be a single therapeutic for all solid tumors.

"We are very encouraged by the initial evaluation of the direct injection of solid tumors with our new product candidate, together with the administration of chemotherapy, in a colon cancer mouse model system," said Dr. Alton Boynton, the company's chief operating and scientific officer. "Although we observed slower colon cancer tumor growth in mice treated with …